Discontinued — last reported Q3 '24
Business Segments · Revenue
Covance Drug Development — Revenue
Labcorp Holdings Covance Drug Development — Revenue increased by 4.3% to $737.70M in Q3 2024 compared to the prior quarter. Year-over-year, this metric grew by 2.6%, from $719.10M to $737.70M. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementSegment
CategoryGrowth
SignalHigher is better
VolatilityStable
First reportedQ1 2013
Last reportedQ3 2024
Rolls up toTotal Revenue
How to read this metric
An increase indicates successful contract wins and growth in demand for drug development services.
Detailed definition
The total gross income generated by the drug development services segment from providing clinical trial support, laborat...
Peer comparison
Standard revenue reporting for CRO segments at peer companies like IQVIA or ICON.
Metric ID:
lh_segment_covance_drug_development_revenuesHistorical Data
11 periods
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.50B | $1.46B | $1.46B | $1.45B | $1.41B | $661.30M | $699.00M | $719.10M | $710.90M | $707.00M | $737.70M |
| QoQ Change | — | -2.4% | -0.0% | -0.5% | -3.2% | -53.0% | +5.7% | +2.9% | -1.1% | -0.5% | +4.3% |
| YoY Change | — | — | — | -2.9% | -3.7% | -54.7% | -51.9% | -48.8% | +7.5% | +1.1% | +2.6% |
Range$661.30M – $1.50B
CAGR-24.6%
Avg YoY Growth-18.8%
Median YoY Growth-3.3%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Labcorp Holdings's covance drug development — revenue?
- Labcorp Holdings (LH) reported covance drug development — revenue of $737.70M in Q3 2024.
- How has Labcorp Holdings's covance drug development — revenue changed year-over-year?
- Labcorp Holdings's covance drug development — revenue increased by 2.6% year-over-year, from $719.10M to $737.70M.
- What does covance drug development — revenue mean?
- Total sales generated by the drug development business segment.